Psychedelics & Mental Health
The Medicine That Governments Won't Quite Let You Have
The most promising psychiatric breakthrough in fifty years is sitting in a scheduling category alongside heroin, and the reason why is less about science than you might hope.
The Idea
When the FDA designates something a Schedule I substance, it formally declares that it has no accepted medical use and a high potential for abuse. Psilocybin, the active compound in so-called magic mushrooms, sits in that category. So does MDMA. The scheduling system in most Western countries was codified in the early 1970s, in a political climate shaped more by the culture wars than by clinical evidence. The science, however, has kept moving — and by now it has moved quite far. The ethical tension this creates is genuinely knotty. On one side: a body of clinical evidence, growing fast, suggesting that carefully guided psychedelic sessions can produce durable relief from treatment-resistant depression, PTSD, and end-of-life anxiety — conditions that conventional pharmacology has struggled with for decades. On the other: real, unresolved questions about who should administer these substances, under what conditions, with what safeguards, and — critically — who gets to profit from turning them into medicines. Because here is what the legal debate often obscures: psilocybin mushrooms grow freely. They have been used ceremonially by indigenous communities for centuries. The pharmaceutical model, which requires patenting synthetic derivatives or proprietary protocols, sits uncomfortably against that history. The fight over legalisation is also, quietly, a fight over who owns a healing practice that was never anyone's to own.
In the World
In 2022, Oregon became the first US state to legalise supervised psilocybin services — not recreational use, but a regulated framework in which trained facilitators guide clients through sessions at licensed centres. It took two years after the ballot measure passed to build the regulatory infrastructure: training standards, facility requirements, screening protocols. The first legal sessions began in mid-2023. What happened next illustrated the ethical complexity almost perfectly. A single session at an Oregon service centre costs somewhere between a week's groceries and a month's rent — often more — putting it well out of reach for most people dealing with the trauma and depression the therapy is meant to treat. The communities who had used these medicines for generations, largely without charge, found themselves watching a new industry form around a practice they never abandoned. Meanwhile, researchers who had spent careers fighting for clinical legitimacy worried that the commercialisation was moving faster than the evidence base for real-world, non-clinical settings could support. Oregon is not a cautionary tale — it is a live experiment in what happens when legal frameworks try to catch up with both scientific possibility and deep ethical debt simultaneously. The results are instructive precisely because they are messy.
Why It Matters
Most discussions about psychedelics and mental health focus on the pharmacology — the serotonin receptors, the default mode network, the mystical experiences that correlate with positive outcomes. That framing quietly sidesteps the fact that whether any of this reaches you, at what cost, and under whose supervision, is entirely a policy question. If you or someone close to you has cycled through antidepressants without finding relief, the legal status of these compounds is not an abstract issue. But even setting aside personal stakes, this is a useful domain for practising a kind of ethical thinking that most of us rarely apply: how do we weigh urgent individual need against societal safeguards we cannot yet fully define? How do we account for cultural harm in a regulatory framework built around clinical trials? And how suspicious should we be when the same institutions that criminalised these substances for half a century are now positioned to profit from their medicalisation? The answers are not obvious. But knowing the shape of the questions makes you a more honest participant in a conversation that is going to matter — for mental healthcare, for drug policy, and for who gets to define what healing looks like.
A Question to Ponder
If a treatment has strong evidence of benefit but limited access due to cost and legal restriction, and an unregulated version of the same thing exists freely in nature — what moral weight does the law actually carry in that situation?
Get a new one of these every morning.
Start learning with Thinkable